Ligand validation:4F9G

C2E: 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one)

C2E is a Ligand Of Interest in 4F9G designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4F9G_C2E_A_401	54%	17%	0.17	0.936	2.4	1.25	16	7	0	0	100%	1
4EF4_C2E_A_401	84%	11%	0.116	0.978	2.82	1.4	16	7	0	0	100%	1
8U0I_C2E_A_102	100%	40%	0.042	0.984	1.15	1.19	6	6	0	0	100%	1
4RT1_C2E_B_201	99%	17%	0.054	0.982	2.38	1.24	11	7	0	0	100%	1
4RT0_C2E_A_202	98%	13%	0.05	0.974	2.34	1.6	11	13	0	0	100%	1
4URG_C2E_A_1241	97%	16%	0.065	0.983	2.24	1.49	10	10	0	0	100%	1
5HTL_C2E_B_201	97%	17%	0.057	0.973	2.34	1.3	15	8	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.